BULLISHWHALES
BullishWhales · Analysts · Analyst Profile
BW Score Rank#139 of 347

Kristen Kluska

Cantor Fitzgerald · Equity Research Analyst
EstablishedRating since 2020No new ratings since May 2025

Analyst rating accuracy & track record

Kristen Kluska is an equity research analyst at Cantor Fitzgerald. Bullish Whales has scored 69 of their stock calls across 21 companies. Their picks beat their sector 39% of the time over the next 12 months, and their price targets were reached 24% of the time within a year.

Win % vs sector
39%
PT Hit % (12mo)
24%
Avg sector-excess
−4.2%
Scored calls
69
Tickers
21
Tier
Established

Track record

Bullish Whales has scored 69 of Kristen Kluska's stock calls across 21 companies, dating back to 2020. Their rated stocks beat their own sector 39% of the time over the next 12 months. On a typical call, a Kluska pick returned −4.2% more than its sector over the following year.

Of the scored calls, 69 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
SLDBSolid Biosciences LLC
Buy$16.00May 2025+118.5%Miss
FULCFulcrum Therapeutics Inc
Buy$10.00May 2025−13.7%Hit
CAPRCapricor Therapeutics Inc
Buy$30.00May 2025+198.6%Hit
ZVRAZevra Therapeutics Inc.
Buy$25.00May 2025+25.1%Miss
TSHATaysha Gene Therapies Inc
Buy$7.00Apr 2025+241.0%Miss
SLNOSoleno Therapeutics Inc
Buy$123.00Mar 2025−59.2%Miss
XFORX4 Pharmaceuticals Inc
Buy$3.00Mar 2025−49.3%Miss
CAPRCapricor Therapeutics Inc
Buy$30.00Mar 2025+125.4%Hit
IRONDisc Medicine Inc.
Buy$132.00Mar 2025+8.1%Miss
MREOMereo BioPharma Group PLC ADR
Buy$7.00Mar 2025−88.3%Miss
ZVRAZevra Therapeutics Inc.
Buy$25.00Mar 2025+22.0%Miss
ADMAADMA Biologics Inc
Buy$25.00Mar 2025−13.2%Hit
RAREUltragenyx
Buy$118.00Feb 2025−53.9%Miss
CLDXCelldex Therapeutics Inc
Buy$67.00Jan 2025−8.5%Miss
RAREUltragenyx
Buy$118.00Jan 2025−59.6%Miss
CLDXCelldex Therapeutics Inc
Buy$67.00Jan 2025−13.1%Miss
ESPREsperion Therapeutics Inc
Buy$8.00Dec 2024+55.0%Miss
AQSTAquestive Therapeutics Inc
Buy$17.00Dec 2024+48.7%Miss
CDXSCodexis Inc
Buy$11.00Nov 2024−73.8%Miss
CDXSCodexis Inc
Buy$11.00Nov 2024−68.8%Miss
CAPRCapricor Therapeutics Inc
Buy$30.00Nov 2024−78.9%Miss
RAREUltragenyx
Buy$116.00Nov 2024−38.3%Miss
ABEOAbeona Therapeutics Inc
Buy$18.00Oct 2024−20.5%Miss
MREOMereo BioPharma Group PLC ADR
Buy$7.00Oct 2024−47.7%Miss
ABEOAbeona Therapeutics Inc
Buy$18.00Sep 2024+3.4%Miss
ADMAADMA Biologics Inc
Buy$20.00Sep 2024−10.0%Hit
SKYESkye Bioscience, Inc. Common Stock
Buy$14.00Sep 2024+21.4%Miss
CDXSCodexis Inc
Buy$11.00Sep 2024−3.8%Miss
CAPRCapricor Therapeutics Inc
Buy$8.00Sep 2024+11.9%Hit
CLDXCelldex Therapeutics Inc
Buy$67.00Sep 2024−28.2%Miss
SLNOSoleno Therapeutics Inc
Buy$67.00Sep 2024+27.5%Hit
CLDXCelldex Therapeutics Inc
Buy$67.00Sep 2024−26.7%Miss
MREOMereo BioPharma Group PLC ADR
Buy$7.00Sep 2024−44.9%Miss
CLDXCelldex Therapeutics Inc
Buy$67.00Sep 2024−29.9%Miss
SKYESkye Bioscience, Inc. Common Stock
Buy$14.00Sep 2024−31.6%Miss
CLDXCelldex Therapeutics Inc
Buy$67.00Sep 2024−32.7%Miss
SKYESkye Bioscience, Inc. Common Stock
Buy$14.00Sep 2024−25.5%Miss
CDXSCodexis Inc
Buy$11.00Aug 2024+5.6%Miss
SKYESkye Bioscience, Inc. Common Stock
Buy$14.00Aug 2024−32.4%Miss
ADMAADMA Biologics Inc
Buy$20.00Aug 2024+10.9%Hit
CDXSCodexis Inc
Buy$11.00Aug 2024+10.6%Miss
MREOMereo BioPharma Group PLC ADR
Buy$7.00Jul 2024−48.8%Miss
FULCFulcrum Therapeutics Inc
Buy$23.00Jul 2024+8.6%Miss
ADMAADMA Biologics Inc
Buy$15.00Jul 2024+58.7%Hit
SKYESkye Bioscience, Inc. Common Stock
Buy$14.00Jul 2024−46.8%Miss
SKYESkye Bioscience, Inc. Common Stock
Buy$14.00Jun 2024−68.5%Miss
SKYESkye Bioscience, Inc. Common Stock
Buy$14.00Jun 2024−71.2%Miss
MREOMereo BioPharma Group PLC ADR
Buy$7.00Jun 2024−25.6%Miss
XFORX4 Pharmaceuticals Inc
Buy$5.00May 2024−80.5%Miss
CDXSCodexis Inc
Buy$11.00May 2024−25.7%Miss
Go to

Kristen Kluska: analyst track record FAQ

Is Kristen Kluska a good stock analyst?

Yes, by track record. Kristen Kluska ranks number 139 of 347 of the analysts Bullish Whales scores, with a BW Score of 37 out of 100. Past results do not guarantee future ones.

What is Kristen Kluska's win rate?

Kristen Kluska's win rate is 39%. Across 69 scored calls, their rated stocks beat their sector 39% of the time over the next 12 months. On a typical call they returned −4.2% more than the sector.

What stocks and sectors does Kristen Kluska cover?

Kristen Kluska covers 21 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Kristen Kluska's price targets accurate?

Kristen Kluska's price targets are reached within 12 months 24% of the time. The base rate across all analysts Bullish Whales tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Bullish Whales scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Kristen Kluska's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Bullish Whales score analyst accuracy?

Bullish Whales scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Kristen Kluska rank among Wall Street analysts?

Kristen Kluska ranks number 139 of 347 by BW Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.

v1.0.30